COGN 201
Alternative Names: COGN-201Latest Information Update: 23 Jul 2025
At a glance
- Originator Cognigenics
- Class Antidementias; Anxiolytics; Gene therapies; Neuropsychotherapeutics; Nootropics; RNA
- Mechanism of Action 5-HT2A serotonin receptor expression inhibitors; Gene expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Cognition disorders
- Research Mild cognitive impairment
Most Recent Events
- 23 Jul 2025 Early research in Mild cognitive impairment in USA (Intranasal), prior to July 2025 (Cognigenics pipeline, July 2025)
- 21 Mar 2024 Pharmacodynamics data from a preclinical trial in Anxiety disorders and Cognition disorders released by Cognigenics
- 21 Mar 2024 Cognigenics plans a clinical trial in Anxiety disorders and Cognition disorders in 2025